Evan W. Warner

1.9k total citations · 1 hit paper
19 papers, 1.2k citations indexed

About

Evan W. Warner is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Evan W. Warner has authored 19 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 14 papers in Cancer Research and 4 papers in Oncology. Recurrent topics in Evan W. Warner's work include Prostate Cancer Treatment and Research (18 papers), Cancer Genomics and Diagnostics (11 papers) and Prostate Cancer Diagnosis and Treatment (8 papers). Evan W. Warner is often cited by papers focused on Prostate Cancer Treatment and Research (18 papers), Cancer Genomics and Diagnostics (11 papers) and Prostate Cancer Diagnosis and Treatment (8 papers). Evan W. Warner collaborates with scholars based in Canada, Finland and United States. Evan W. Warner's co-authors include Alexander W. Wyatt, Kim N., Kevin Beja, Matti Annala, Martin Gleave, Matti Nykter, Gillian Vandekerkhove, Daniel Khalaf, Arun Azad and Bernhard J. Eigl and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Evan W. Warner

19 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

2018 347 citations Matti Annala, Gillian Vandekerkhove et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Evan W. Warner Canada	10	1.0k	672	388	342	136	19	1.2k
Daniel Khalaf Canada	12	1.1k 1.0×	590 0.9×	411 1.1×	300 0.9×	234 1.7×	41	1.2k
John L. Silberstein United States	12	728 0.7×	323 0.5×	413 1.1×	314 0.9×	126 0.9×	16	1.0k
Sinja Taavitsainen Finland	9	702 0.7×	458 0.7×	247 0.6×	248 0.7×	135 1.0×	17	899
Joanna Vergidis Canada	12	772 0.7×	386 0.6×	334 0.9×	215 0.6×	201 1.5×	27	980
Kevin Beja Canada	16	1.4k 1.3×	1.0k 1.5×	545 1.4×	552 1.6×	157 1.2×	25	1.7k
Jessica Louw United States	9	692 0.7×	532 0.8×	479 1.2×	249 0.7×	114 0.8×	30	988
Katherine Sunderland Canada	10	694 0.7×	331 0.5×	230 0.6×	161 0.5×	190 1.4×	23	761
Mari Nakazawa United States	10	836 0.8×	434 0.6×	265 0.7×	334 1.0×	192 1.4×	25	1.0k
Pier Vitale Nuzzo United States	16	500 0.5×	298 0.4×	389 1.0×	382 1.1×	44 0.3×	58	943
Edmond M. Kwan Australia	13	462 0.4×	330 0.5×	188 0.5×	161 0.5×	115 0.8×	62	622

Countries citing papers authored by Evan W. Warner

Since Specialization

Citations

This map shows the geographic impact of Evan W. Warner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evan W. Warner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evan W. Warner more than expected).

Fields of papers citing papers by Evan W. Warner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evan W. Warner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evan W. Warner. The network helps show where Evan W. Warner may publish in the future.

Co-authorship network of co-authors of Evan W. Warner

This figure shows the co-authorship network connecting the top 25 collaborators of Evan W. Warner. A scholar is included among the top collaborators of Evan W. Warner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evan W. Warner. Evan W. Warner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Sumiyoshi, Takayuki, Xiaofei Wang, Evan W. Warner, et al.. (2023). Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial. JNCI Journal of the National Cancer Institute. 116(1). 115–126. 2 indexed citations

Ritch, Elie, Cameron Herberts, Evan W. Warner, et al.. (2023). A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes. npj Precision Oncology. 7(1). 27–27. 6 indexed citations

Jiang, Di, Bryan Wong, Tong Zhang, et al.. (2022). Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targets. Clinical Genitourinary Cancer. 20(3). 278–284. 2 indexed citations

Warner, Evan W., Kim Van der Eecken, Andrew J. Murtha, et al.. (2022). Abstract 41: Multi-focal genomic dissection of synchronous primary and metastatic tissue from de novo metastatic prostate cancer. Cancer Research. 82(12_Supplement). 41–41. 1 indexed citations

Annala, Matti, Sinja Taavitsainen, Daniel Khalaf, et al.. (2021). Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clinical Cancer Research. 27(16). 4610–4623. 52 indexed citations

Warner, Evan W., Cameron Herberts, Simon Fu, et al.. (2021). BRCA2 , ATM , and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. Clinical Cancer Research. 27(6). 1650–1662. 52 indexed citations

Eecken, Kim Van der, Matthew P. Deek, Phuoc T. Tran, et al.. (2021). Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review. European Urology Oncology. 4(6). 914–923. 25 indexed citations

Warner, Evan W., Steven Yip, Matti Annala, et al.. (2020). Abstract PR09: Frequency and etiology of ctDNA-positive metastatic prostate cancer with BRCA2, ATM, or CDK12 mutations. Clinical Cancer Research. 26(11_Supplement). PR09–PR09. 1 indexed citations

Vandekerkhove, Gillian, Werner J. Struss, Matti Annala, et al.. (2019). Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. European Urology. 75(4). 667–675. 134 indexed citations

10.

Yip, Steven, Katherine Sunderland, Arkhjamil Angeles, et al.. (2019). Predictors of germline DNA damage repair gene mutations (gDDRm) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 37(7_suppl). 159–159. 1 indexed citations

11.

Annala, Matti, Gillian Vandekerkhove, Daniel Khalaf, et al.. (2018). Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discovery. 8(4). 444–457. 347 indexed citations breakdown →

12.

Warner, Evan W., Steven Yip, Kim N., & Alexander W. Wyatt. (2018). DNA repair defects in prostate cancer: impact for screening, prognostication and treatment. British Journal of Urology. 123(5). 769–776. 25 indexed citations

13.

Yip, Steven, Daniel Khalaf, Werner J. Struss, et al.. (2018). Outcomes in patients (Pts) with advanced prostate cancer and inactivating germline mutations in BRCA2 or ATM.. Journal of Clinical Oncology. 36(6_suppl). 242–242. 3 indexed citations

14.

Beltran, Himisha, Alexander W. Wyatt, Edmund C.P. Chedgy, et al.. (2017). Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clinical Cancer Research. 23(22). 6802–6811. 52 indexed citations

15.

Annala, Matti, Werner J. Struss, Evan W. Warner, et al.. (2017). Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer. European Urology. 72(1). 34–42. 169 indexed citations

16.

Struss, Werner J., Matti Annala, Evan W. Warner, et al.. (2017). Germline DNA repair mutations in metastatic castration-resistant prostate cancer: Therapy response and applicability of circulating tumor DNA.. Journal of Clinical Oncology. 35(6_suppl). 140–140. 2 indexed citations

17.

Wyatt, Alexander W., Arun Azad, Stanislav Volik, et al.. (2016). Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. JAMA Oncology. 2(12). 1598–1598. 266 indexed citations

18.

Wyatt, Alexander W., Matti Annala, Kevin Beja, et al.. (2016). Genomic alterations in circulating tumor DNA (ctDNA) are associated with clinical outcomes in treatment-naive metastatic castration-resistant prostate cancer (mCRPC) patients commencing androgen receptor (AR)-targeted therapy. Annals of Oncology. 27. vi17–vi17. 3 indexed citations

19.

Chedgy, Edmund C.P., Matti Annala, Kevin Beja, et al.. (2015). Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer. Clinical Genitourinary Cancer. 14(2). e233–e236. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact